Furthermore, analysis of data from the RCC clinical trial IMmotion151[22] revealed that high SMYD3 expression was associated with a lower ICI response rate (OR: 1.927; 95% CI: 0.9963–3.650), and the non‐responsive group had greater infiltration of Th2 cells than the responsive group did (Figure 2G,H). The gene discussed is SMYD3; the disease is renal cell carcinoma.